CRISPR-Cas9 for selective targeting of somatic mutations in pancreatic cancers.
Teh SSK, Bowland K, Halper-Stromberg E, Kotwal A, Bennett A, Skaist A, Tang J, Cai F, Macoretta A, Liang H, Kamiyama H, Wheelan S, Lin MT, Hruban RH, Hung CF, Goldstein M, Scharpf RB, Roberts NJ, Eshleman JR
NAR Cancer. 2024 Jun 19;6(2):zcae028. doi: 10.1093/narcan/zcae028. eCollection 2024 Jun.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 193780 | pLentiCas9-T2A-mApple | Tricistronic expression of Cas9-mApple-BSD in mammalian cells |
| 193781 | pLenti-dCas9-T2A-GFP | Tricistronic expression of dCas9-EGFP-BSD |
| 200941 | lentiGuide-puro_Panc480-MT7 | Multiplexed CRISPR array expressing 7 sgRNA in a lentiviral backbone |
| 211471 | pLenti_Cas9_T2A_mNeonGreen_P2A_blasticidin | lentiviral tricistronic complex expressing Cas9, mNeonGreen, and blasticidin resistance |